



CLINICAL CONSULTING TEAM



Jack M. Gorman, MD

Dr. Gorman MD is a key medical consultant for Care Management Technologies. He founded Franklin Behavioral Healthcare Consultants in 2010. He is currently CEO and Chief Scientific Officer. Franklin Behavioral Healthcare Consultants provides expert guidance to biotech companies and to health care organizations.

Before founding Franklin Behavioral Healthcare Consultants, Dr. Gorman was Chief Scientific Officer and Senior Vice-President of both Comprehensive NeuroScience, Inc. and Care Management Technologies Inc. In those positions he used his two decades of experience in neuroscience, psychiatry, and psychopharmacology to help develop new programs in behavioral health care management and CNS drug development.

Dr. Gorman was a summa cum laude graduate of the University of Pennsylvania, received his medical degree from the College of Physicians and Surgeons of Columbia University and completed residency and fellowship training in the Department of Psychiatry of Columbia University/New York State Psychiatric Institute program. He was on the faculty of Columbia University from 1981 to 2002, becoming Lieber Professor, Vice-chair for Research and Director of the Lieber Center for Schizophrenia Research. He then became Klingenstein Professor and Chair of the Department of Psychiatry of the Mount Sinai School of Medicine. Dr. Gorman was elected a fellow of the American College of Neuropsychopharmacology, has authored or co-authored more than 400 scientific articles and chapters, and was continuously funded by the National Institutes of Health for his research from 1981 until 2006 and received three research grants from the Brain and Behavior Institute (formerly NARSAD). He won numerous awards for his research and service to psychiatry from organizations like the American Psychiatric Association, American College of Neuropsychopharmacology, Mental Illness Foundation, and Society for Cognitive Behavioral Therapy and is one of the most frequently cited authors in the psychiatry and neuroscience literatures. Dr. Gorman is co-editor of the textbooks *Treatments that Work*, now in its third edition, and *Comprehensive Textbook of AIDS Psychiatry* and author of the popular book *The Essential Guide to Psychiatric Drugs*, which appeared in its fourth edition in 2007. His expertise is in behavioral healthcare management and improvement, psychopharmacology, and clinical and basic neuroscience.



Christopher Reist, MD MBA

Dr. Reist is an Associate Professor (with tenure) in the Department of Psychiatry and Human Behavior at the University of California, Irvine. He also serves as Assistant Dean in the College of Medicine and the Director of Medical Research for the Long Beach Veterans Affairs Healthcare System. Formerly he served as Chief of Mental Health, overseeing full service mental health care delivery to over 40,000 enrollees at the Long Beach VA Healthcare System. For the past 12 years he has served as Associate Director of the Southern California VA Mental Illness Research, Education and Clinical Center (MIRECC) which is focused on improving long term outcomes in chronic psychotic disorders through basic/clinical research and dissemination of evidence-based practices.

Dr. Reist received his undergraduate degree in chemistry and biology at Eastern Mennonite University in Harrisonburg, Virginia. Following medical training at the Medical College of Virginia in Richmond, Virginia, he completed his psychiatry residency at the University of California, Irvine. Additionally, he attained a MBA from the Anderson School of Management at the University of California in Los Angeles.

Dr. Reist's clinical interests include schizophrenia, impulsivity, PTSD, pharmacogenomics, and psychopharmacology. NARSAD, NIMH, and VA Medical Research have supported his research. He has served as principal investigator on over 25 clinical trials in areas including schizophrenia, depression, bipolar disorder and impulsivity. He is a member of professional societies including the American Psychiatric Association, Pacific Rim Association for Clinical Pharmacogenetics and the Society of Biological Psychiatry. He is a Distinguished Fellow of the Psychiatric Association, has been recognized as an Exemplary Psychiatrist by the National Alliance for the Mentally Ill and is included in *Best Doctors*, 2007-2010. He is the author of two books, *Psychiatry* and *Psychiatric Drugs* which have been widely used by trainees for the past 15 years. He has over 50 scientific articles that have been published in high impact journals including *Molecular Psychiatry*, *Biological Psychiatry*, *Journal of Clinical Psychiatry*, *American Journal of Psychiatry*, and *Nature Biotechnology*. Lastly, he has extensive experience in psychiatric education that include organizing CME conferences (www.mirecc.va.gov/visn22) and developing web content that provide information on psychiatric disorders and treatment.



George Oestreich, PharmD

Dr. Oestreich is providing key strategic consulting on Medicaid issues including health information technology, decision support, program design and care coordination policy development. A major interest is developing transparent integrated patient care management and coordination solutions into current practice. He has unique and comprehensive experience in pharmacy benefit design coupling integrated pharmacy services into mainstream care coordination and service delivery.

Dr. Oestreich served as Deputy Division Director, Clinical Services, for MO HealthNet (MHD), the Missouri Medicaid agency from August 2006 until February 2011. In this position he developed clinical payment policy and related payment edits. He coordinated health information technology for monitoring, support of edits and decision support. Also in his venue was the development and implementation of disease management and care coordination services. The later resulted in a positive return on investment and improved patient outcome indicators.

Dr. Oestreich served as Director of Pharmacy for the agency from 2001 to 2006. Under his leadership, the MHD was an early innovator in Medicaid pharmacy programs integrating aggressive maximum allowable pricing, clinically sound step therapy, productive supplemental rebate programs, high tech prior authorization and physician-pharmacist disease management. These programs provided cost avoidance for the agency that averaged over \$100 million annually. In a recent program review the Lewin Group stated, "Pharmacy program leadership staff have an exceptional level of Medicaid and prescription drug management expertise and stand out among Medicaid pharmacy staff nationwide"

During his tenure as Deputy Director of Clinical Services, he has continued providing effective leadership that extends the principals of the incorporation of medical evidence and best practice into the polices of other service areas. The most synergistic have been the integration of high tech solutions into care coordination opportunities. That process has produced greater savings than traditional disease management by focusing on opportunities within targeted disease processes that can be impacted. In this space, Dr. Oestreich has also used population-based queries of integrated claim data to support program initiatives and promulgate policy. Significant increases in patient health status as well as actual short term cost savings and projected long-term savings have been achieved.

From September 2009 until leaving the agency, Dr. Oestreich served as Project Director for Missouri's healthcare technology grant from the Office of the National Coordinator (ARRA HITEC) as well as the coordinating the states state Medicaid technology initiatives (IAPD and SMHP). The MHD initiatives are yielding a coordinated approach by integrating paid claim data with clinical data. This integrated approach is then presented to state staff for program management and contracted provider clinical staff for coordinated decision support.

One major area of focus since engaging full time in private consulting has been in the 340B drug discount space. Recent changes in the 340B drug discount program have caused an exponential growth in contract pharmacies and associated third party prescription claims adjudication issues. Of particular interest has been the appropriate use of 340B drugs in Medicaid and how to assure duplications with drug rebate discounts do not occur. Of concern are the methodologies previously developed for assuring that only patients of covered entities receive access to the products.

Dr. Oestreich has worked extensively on these and related issues on the behalf of national clients, state agencies and small providers. Unique targeted solutions have proven to be the most effective. As a by-product of this work he has provided articles, presentations, and targeted solutions for unique settings for the use of 340B-discounted drugs.

Dr. Oestreich earned his BS in Pharmacy from the University of Missouri-KC, his Master of Public Administration from University of Missouri-Columbia and his Doctor of Pharmacy from Kansas University. Prior to joining state government in 2001 as he served as Chief Executive Officer of the Missouri Pharmacy Association and the Foundation for Pharmaceutical Care for 13 years. He has a wide variety of pharmacy practice experience in community, hospital, long term care and consulting. He owned a full service community pharmacy until 2007 working and managing it until 1989 when he began working for the association. He served on the Missouri Board of Pharmacy for five years, and as President for 2 of those years. He has received many awards, made multitudes of presentations and co-authored many publications.



Jennifer Kemp-Cornelius, RPh, BS Pharm, PharmD

Dr. Kemp-Cornelius has over two and half decades of pharmacy practice experience and years of community pharmacy experience. She has over twelve years of major state contract management experience, significant experience in long-term care pharmacy consulting and community pharmacy experience spanning the entire continuum of practice. Dr. Kemp-Cornelius served as account manager for the MOHealthNet (MHD) clinical services contract provided by Xerox. This contract began as 5 million dollar retrospective DUR contract and pharmacy edit program with a component of disease management. Over her tenure it morphed into a \$17 million dollar clinical services program that produced a cutting edge paid claim provider portal that interfaced with a clinical rules engine that juried claims electronically for the majority of MHD services. Additionally the Xerox services interfaced with a hospital precertification program, and a home and community based services program (administered by a sister agency). The system provided an interface for pharmacists to provide and bill for medication therapy management services, unique to other states. Patient care portal was also a by-product of the work and is used extensively in the state's health home initiative. Supporting all of these services was an integrated help desk that supported deployment and provider operations.

The produced saving projections supported by these services at over a quarter of a billion dollars annually. The system is a part of the reason the state's Lewin report cited the state's pharmacy program as one the best nationally. Many states have used some of these tools to support their program but none have replicated the integration and multi-departmental operations.

The Xerox tools were integral for the space to achieve its first integration of health records over the health information exchange initiative. With Dr. Kemp-Cornelius's operational oversight, the state used the MHD program as the basis for ramping up the functionality of the exchange. The contract was also the vehicle the state chose to support the electronic health records grant program supported by CMS and the ONC.

Dr. Kemp-Cornelius joined the G.L.O. and Associates consulting group in July 2014. Since that time she has not only supported ongoing contracts over a variety of initiatives but has developed her specific client base in the process. Currently she is consulting with a technology vendor to help incorporate an analytic web tool and ad hoc reporting into daily operations for a chronic pain management program, a pharmacy integration project for diabetes and hypertension outcomes, and a health home program. She is also working with a state pharmacy network to provide extensive training for pharmacists interested in supporting patient wellness programs in concert with CDC grants. These programs train, monitor and report on the effectiveness and efficacy of pharmacists service primarily in patients with hypertension and diabetes. Dr. Kemp-Cornelius was previously responsible for account management, service delivery, and operations for the Xerox contract with MO HealthNet. Responsibilities included working collaboratively with Xerox's IT

department to drive major installations and system updates, managing a retrospective DUR program, managing the process for developing, testing and placing into production new prospective clinical and fiscal editing criteria for pharmacy and medical programs, overseeing the implementation of an inpatient pre-certification system and clinical helpdesk, overseeing deployment and operations of provider and patient electronic health record portals, and overseeing provider outreach and training on new web modules and programs.

Prior to working for Xerox, Dr. Kemp-Cornelius practiced both as a staff pharmacist and then as a pharmacy manager (pharmacist in charge) for one of the busiest chain community pharmacies in the state. She is a licensed pharmacist in the State of Missouri and completed training to be certified by the board of pharmacy in Medication Therapy Services (a program that allows pharmacists to provide clinical services directly to patients using a protocol with a physician).

Dr. Kemp-Cornelius received both her Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees from the St. Louis College of Pharmacy. She is married and has three children.



Johnny Bethea, BS Pharm

Johnny Bethea brings balanced experience to CMT from the pharmaceutical industry and retail pharmacy. He has earned B.S. Pharmacy degree from the College of Pharmacy at the Medical University of South Carolina in 1992. He has earned certificates in Medication Therapy Management and Asthma Therapy Management. Johnny currently serves as Pharmacy Manager of Student Health Services Pharmacy at North Carolina Central University. His past experience includes serving as Psychiatric and Cardiovascular Consultant Pharmacist at PPD Communications and as a Pharmaceutical Representative for Eli Lilly and Company. Johnny has served as President of the Durham Academy of Medicine, Dentistry and Pharmacy. He is a past member of the Executive Board and chaired the Formulary Committee for the non-profit organization Senior PharmAssist. He also currently serves on the Building Leadership Committee for South Carolina College of Pharmacy.